REVIEW ARTICLE
Progress of clinical research studies on tuberous sclerosis complex-related epilepsy in China
Tinghong Liu,
Feng Chen,
Feng Zhai,
Shuli Liang,
Tinghong Liu
Functional Neurosurgery Department, National Children's Health Center of China, Beijing Children's Hospital, Capital Medical University, Beijing, China
Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China
Search for more papers by this authorFeng Chen
Functional Neurosurgery Department, National Children's Health Center of China, Beijing Children's Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorFeng Zhai
Functional Neurosurgery Department, National Children's Health Center of China, Beijing Children's Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorCorresponding Author
Shuli Liang
Functional Neurosurgery Department, National Children's Health Center of China, Beijing Children's Hospital, Capital Medical University, Beijing, China
Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China
Correspondence
Shuli Liang, Functional Neurosurgery Department, National Center for Children's Health of China, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Email: [email protected]
Search for more papers by this authorTinghong Liu,
Feng Chen,
Feng Zhai,
Shuli Liang,
Tinghong Liu
Functional Neurosurgery Department, National Children's Health Center of China, Beijing Children's Hospital, Capital Medical University, Beijing, China
Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China
Search for more papers by this authorFeng Chen
Functional Neurosurgery Department, National Children's Health Center of China, Beijing Children's Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorFeng Zhai
Functional Neurosurgery Department, National Children's Health Center of China, Beijing Children's Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorCorresponding Author
Shuli Liang
Functional Neurosurgery Department, National Children's Health Center of China, Beijing Children's Hospital, Capital Medical University, Beijing, China
Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China
Correspondence
Shuli Liang, Functional Neurosurgery Department, National Center for Children's Health of China, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Email: [email protected]
Search for more papers by this authorTinghong Liu and Feng Chen are co-first authors.
Abstract
Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous syndrome, with 75.6%–83.5% and 54.1% patients presenting with epilepsy and drug-resistant epilepsy (DRE), respectively. Clinical studies on TSC, particularly surgical interventions, have achieved rapid and substantial progress. The TSC-Task Force Committee of the China Association Against Epilepsy (CAAE-TFTSC) was founded in 2012, and annual academic conferences on the surgical treatment of TSC-related epilepsy have been held since 2013. ‘China experts' consensus on surgical treatment of TSC-related epilepsy’ was published in 2019. This review focuses on surgical treatment, including resective surgery, neuromodulations, corpus callosotomy and mini-invasive ablations, as well as studies on phenotype, genotype and anti-seizure therapies of mammalian target of rapamycin inhibitor, vigabatrin and ketogenic diet in patients with TSC-related DRE in China.
CONFLICT OF INTEREST
None of the authors has any competing interest to disclose.
Open Research
DATA AVAILABILITY STATEMENT
Not available.
RESPONSE TO PEER REVIEW TRANSPARENCY OPTION (reviewer reports, author responses, and decision letter linked from Publons): Agree
REFERENCES
- 1Liu S, Yu T, Guan Y, et al. Resective epilepsy surgery in tuberous sclerosis complex: a nationwide multicentre retrospective study from China. Brain. 2020; 143(2): 570-581. doi:10.1093/brain/awz411
- 2Ding P, Liang S. Diagnosis of tuberous sclerosis complex and non-surgery treatment for tuberous sclerosis complex related epilepsy. Dian Xian Za Zhi. 2019; 5(2): 120-124 [in Chinese]. doi:10.7507/2096-0247.20190022
10.7507/2096-0247.20190022 Google Scholar
- 3 Professional Committee of Tuberous Sclerosis Complex, China Anti-Epilepsy Association. Chinese expert consensus on surgical treatment of tuberous sclerosis complex-related epilepsy. Zhongguo Dang Dai Er Ke Za Zhi. 2019; 21(8): 735-742 [in Chinese]. doi:10.7499/j.issn.1008-8830.2019.08.001
- 4Yang G, Shi Z, Meng Y, et al. Phenotypic and genotypic characterization of Chinese children diagnosed with tuberous sclerosis complex. Clin Genet. 2017; 91(5): 764-768. doi:10.1111/cge.12920
- 5Lin S, Zeng J, Zhao G, et al. Tuberous sclerosis complex in Chinese patients: phenotypic analysis and mutational screening of TSC1/TSC2 genes. Seizure. 2019; 71: 322-327. doi:10.1016/j.seizure.2019.08.010
- 6Su Y, Wei Q, Wan J, Li L. Tuberous sclerosis complex: early screening and infant outcome in NICU. J Trop Pediatr. 2021; 67(1):fmab012. doi:10.1093/tropej/fmab012
- 7Ding Y, Zhou Y, Yu L, et al. Correlation between epilepsy and genotype: a large retrospective tuberous sclerosis complex cohort. Seizure. 2021; 91: 273-277. doi:10.1016/j.seizure.2021.06.036
- 8Wang Y, Pang L, Ma S, Zhang M, Liu L, Zou L. Epilepsy may be the major risk factor of mental retardation in children with tuberous sclerosis: a retrospective cohort study. Epilepsy Behav. 2017; 77: 13-18. doi:10.1016/j.yebeh.2017.09.017
- 9Ding Y, Wang J, Zhou Y, et al. Quality of life in children with tuberous sclerosis complex: a pediatric cohort study. CNS Neurosci Ther. 2021; 27(3): 280-288. doi:10.1111/cns.13473
- 10Cui J, Yu X, Liang S, Zhang S, Hu X. First five generations Chinese family of tuberous scleroses complex due to a new mutation of the TSC1 gene. J Clin Neurosci. 2018; 54: 39-44. doi:10.1016/j.jocn.2018.05.007
- 11He J, Zhou W, Shi J, Lin J, Zhang B, Sun Z. Analysis of genotypes, EEG and phenotypes of tuberous sclerosis complex patients. Zhonghua Yi Xue Za Zhi. 2020; 100(2): 136-140 [in Chinese]. doi:10.3760/cma.j.issn.0376-2491.2020.02.011
- 12Bai D, Zhao J, Li L, Gao J, Wang X. Analysis of genotypes and phenotypes in Chinese children with tuberous sclerosis complex. Sci China Life Sci. 2017; 60(7): 763-771. doi:10.1007/s11427-017-9091-x
- 13He W, Chen J, Wang Y, et al. Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: a prospective cohort study. Seizure. 2020; 79: 20-26. doi:10.1016/j.seizure.2020.03.018
- 14Shen Y, Wang Y, Zhang M, et al. Sirolimus treatment for tuberous sclerosis complex prior to epilepsy: evidence from a registry-based real-world study. Seizure. 2022; 97: 23-31. doi:10.1016/j.seizure.2022.03.003
- 15Li M, Zhou Y, Chen C, et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J Rare Dis. 2019; 14(1): 39. doi:10.1186/s13023-019-1012-x
- 16Samueli S, Abraham K, Dressler A, et al. Efficacy and safety of Everolimus in children with TSC - associated epilepsy - pilot data from an open single-center prospective study. Orphanet J Rare Dis. 2016; 11(1): 145. doi:10.1186/s13023-016-0530-z
- 17French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016; 388(10056): 2153-2163. doi:10.1016/S0140-6736(16)31419-2
- 18Wiegand G, May TW, Lehmann I, Stephani U, Kadish NE. Long-term treatment with everolimus in TSC-associated therapy-resistant epilepsies. Seizure. 2021; 93(93): 111-119. doi:10.1016/j.seizure.2021.10.011
- 19Stockinger J, Strzelczyk A, Nemecek A, et al. Everolimus in adult tuberous sclerosis complex patients with epilepsy: too late for success? A retrospective study. Epilepsia. 2021; 62(3): 785-794. doi:10.1111/epi.16829
- 20Franz DN, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: results from the postextension phase of EXIST-3. Epilepsia. 2021; 62(12): 3029-3041. doi:10.1111/epi.17099
- 21Overwater IE, Rietman AB, Bindels-de Heus K, et al. Sirolimus for epilepsy in children with tuberous sclerosis complex: a randomized controlled trial. Neurology. 2016; 87(10): 1011-1018. doi:10.1212/WNL.0000000000003077
- 22Lu Q, Wang Y, Wang Q, et al. Safety of inactivated COVID-19 vaccine in tuberous sclerosis complex patients with epilepsy treated with rapamycin. Seizure. 2022; 99: 71-74. doi:10.1016/j.seizure.2022.05.010
- 23Wang D, Chen X, Xu H, Li Z. Initial dosage recommendation for sirolimus in children with tuberous sclerosis complex. Front Pharmacol. 2020; 11: 890. doi:10.3389/fphar.2020.00890
- 24Chen X, Wang D, Zhu L, et al. Population pharmacokinetics and initial dose optimization of sirolimus improving drug blood level for seizure control in pediatric patients with tuberous sclerosis complex. Front Pharmacol. 2021; 12:647232. doi:10.3389/fphar.2021.647232
- 25Lin S, Liao J, Zhao X, et al. Focal epilepsy in children with tuberous sclerosis complex: does vigabatrin control focal seizures? J Child Neurol. 2022; 37(5): 329-333. doi:10.1177/08830738211048326
- 26Zhang L, Zhou H, Lu T, et al. Vigabatrin for epilepsy in children with tuberous sclerosis complex: an analysis of 25 case in mainland of China. Dian Xian Za Zhi. 2016; 2(2): 109-113 [in Chinese]. doi:10.7507/2096-0247.20160020
10.7507/2096-0247.20160020 Google Scholar
- 27Lv H, Chen Y, Zhang Y. Effect of vegabatrin on infantile spasm in children with tuberous sclerosis complex. Yin Shi Bao Jian. 2020; 7(24): 5-6 [in Chinese].
- 28Fang Y, Li D, Wang M, et al. Ketogenic diet therapy for drug-resistant epilepsy and cognitive impairment in children with tuberous sclerosis complex. Front Neurol. 2022; 13:863826. doi:10.3389/fneur.2022.863826
- 29Zhang M, Zou L, Wang Y, et al. Calcification in cerebral parenchyma affects pharmacoresistant epilepsy in tuberous sclerosis. Seizure. 2018; 60: 86-90. doi:10.1016/j.seizure.2018.06.011
- 30Liang S, Zhang J, Yang Z, et al. Long-term outcomes of epilepsy surgery in tuberous sclerosis complex. J Neurol. 2017; 264(6): 1146-1154. doi:10.1007/s00415-017-8507-y
- 31Li Q, You C, Fang Y, Xu J. Multimodal approach in the surgical treatment of refractory epilepsy associated with tuberous sclerosis complex: a series of three cases. Neurol India. 2011; 59(5): 748-752. doi:10.4103/0028-3886.86553
- 32Zhao G, Shan Y, Du J, Ling F. Epilepsy surgery for tuberous sclerosis complex: a case report and literature review. Chin Med J (Engl). 2008; 121(10): 959-960.
- 33Liu S, Cai Y, Rong R, et al. Tuberous sclerosis complex (TSC) with epilepsy on 18F-FDG simultaneous PET/MR. Eur J Nucl Med Mol Imaging. 2020; 47(10): 2471-2472. doi:10.1007/s00259-019-04539-6
- 34Sun K, Cui J, Xue R, et al. New imaging features of tuberous sclerosis complex: a 7 T MRI study. NMR Biomed. 2021; 34(9):e4565. doi:10.1002/nbm.4565
- 35Sun K, Cui J, Wang B, et al. Magnetic resonance imaging of tuberous sclerosis complex with or without epilepsy at 7 T. Neuroradiology. 2018; 60(8): 785-794. doi:10.1007/s00234-018-2040-2
- 36Liu T, Chen H, Zhang G, Fang F, Xue R, Liang S. Interpretation of “7T epilepsy task force consensus recommendations on the use of 7T MRI in clinical practice”. Dian Xian Za Zhi. 2021; 7(2): 136-141 [in Chinese]. doi:10.7507/2096-0247.20210023
- 37Wen Q, Wang K, Hsu Y, et al. Chemical exchange saturation transfer imaging for epilepsy secondary to tuberous sclerosis complex at 3 T: optimization and analysis. NMR Biomed. 2021; 34(9):e4563. doi:10.1002/nbm.4563
- 38Huang Q, Zhou J, Wang X, et al. Predictors and long-term outcome of resective epilepsy surgery in patients with tuberous sclerosis complex: a single-centre retrospective cohort study. Seizure. 2021; 88: 45-52. doi:10.1016/j.seizure.2021.03.022
- 39Liang S, Liang C, Zhao M, et al. Surgical treatment for epilepsy in patients with tuberous sclerosis complex. Dian Xian Yu Shen Jing Dian Sheng Li Za Zhi. 2010; 19(2): 81-84 [in Chinese].
- 40Yu X, Ding P, Yuan L, et al. Cortico-cortical evoked potentials in children with tuberous sclerosis complex using stereo-electroencephalography. Front Neurol. 2019; 10: 1093. doi:10.3389/fneur.2019.01093
- 41Wang Y, Yuan L, Zhang S, et al. Fast ripples as a biomarker of epileptogenic tuber in tuberous sclerosis complex patients using stereo-electroencephalograph. Front Hum Neurosci. 2021; 15:680295. doi:10.3389/fnhum.2021.680295
- 42Liang S, Chen F, Liu T. Surgical treatment in children with genetic epilepsy. Zhong Guo Xian Dai Yi Xue Za Zhi. 2021; 31(19): 1-6 [in Chinese]. doi:10.3969/j.issn.1005-8982.2021.19.001
10.3969/j.issn.1005-8982.2021.19.001 Google Scholar
- 43Liu S, An N, Yang M, et al. Surgical treatment for epilepsy in 17 children with tuberous sclerosis-related west syndrome. Epilepsy Res. 2012; 101(1–2): 36-45. doi:10.1016/j.eplepsyres.2012.02.017
- 44Liang S, Li A, Fu X, Geng F. Combined surgery in patients with tuberous sclerosis complex related intractable epilepsy: 3 cases repot. Zhong Guo Wei Qin Xi Shen Jing Wai Ke Za Zhi. 2003; 8(10): 474 [in Chinese].
- 45Liu S, An N, Yang H, et al. Surgery of infantile spasms with tuberous sclerosis complex. Zhong Guo Lin Chuang Shen Jing Wai Ke Za Zhi. 2010; 18(8): 489-491 [in Chinese]. doi:10.3969/j.issn.1009-153X.2010.08.014
- 46Liang S, Li A, Zhao M, et al. Epilepsy surgery in tuberous sclerosis complex: emphasis on surgical candidate and neuropsychology. Epilepsia. 2010; 51(11): 2316-2321. doi:10.1111/j.1528-1167.2010.02669.x
- 47Yuan L, Wang Y, Cheng S, et al. Interictal discharge pattern in preschool-aged children with tuberous sclerosis complex before and after resective epilepsy surgery. Front Neurol. 2022; 13:868633. doi:10.3389/fneur.2022.868633
- 48He J, Shi J, Lin J, et al. Surgical treatment of tuberous sclerosis with refractory epilepsy in children. Zhong Hua Lin Chuang Yi Shi Za Zhi. 2021; 15(8): 597-600. doi:10.3877/cma.j.issn.1674-0785.2021.08.007
10.3877/cma.j.issn.1674-0785.2021.08.007 Google Scholar
- 49Zhang K, Hu W, Zhang C, Meng F, Chen N, Zhang J. Predictors of seizure freedom after surgical management of tuberous sclerosis complex: a systematic review and meta-analysis. Epilepsy Res. 2013; 105(3): 377-383. doi:10.1016/j.eplepsyres.2013.02.016
- 50Yue J, Zhang C, Shi X, et al. Activation of leukocyte immunoglobulin-like receptor B2 signaling pathway in cortical lesions of pediatric patients with focal cortical dysplasia type IIb and tuberous sclerosis complex. Brain Dev. 2019; 41(10): 829-838. doi:10.1016/j.braindev.2019.08.002
- 51Wu K, Yue J, Shen K, et al. Expression and cellular distribution of FGF13 in cortical tubers of the tuberous sclerosis complex. Neurosci Lett. 2021; 749:135714. doi:10.1016/j.neulet.2021.135714
- 52Wang Z, Huang K, Yang X, et al. Downregulated GPR30 expression in the epileptogenic foci of female patients with focal cortical dysplasia type IIb and tuberous sclerosis complex is correlated with 18F-FDG PET-CT values. Brain Pathol. 2021; 31(2): 346-364. doi:10.1111/bpa.12925
- 53Yu S, Li S, Shu H, Zhang C, Liu S, Yang H. Expression of the Nogo-a system in cortical lesions of pediatric patients with tuberous sclerosis complex and focal cortical dysplasia type IIb. J Neuropathol Exp Neurol. 2012; 71(7): 665-677. doi:10.1097/NEN.0b013e31825d6585
- 54Shu H, Zhang C, Yin Q, An N, Liu S, Yang H. Expression of the interleukin 6 system in cortical lesions from patients with tuberous sclerosis complex and focal cortical dysplasia type IIb. J Neuropathol Exp Neurol. 2010; 69(8): 838-849. doi:10.1097/NEN.0b013e3181eaeae5
- 55Chen X, Yang M, Sun F, et al. Expression and cellular distribution of transient receptor potential vanilloid 4 in cortical tubers of the tuberous sclerosis complex. Brain Res. 2016; 1636: 183-192. doi:10.1016/j.brainres.2016.02.012
- 56Shu H, Yu S, Zhang C, et al. Expression of TRPV1 in cortical lesions from patients with tuberous sclerosis complex and focal cortical dysplasia type IIb. Brain Dev. 2013; 35(3): 252-260. doi:10.1016/j.braindev.2012.04.007
- 57Li S, Yu S, Zhang C, et al. Increased expression of matrix metalloproteinase 9 in cortical lesions from patients with focal cortical dysplasia type IIb and tuberous sclerosis complex. Brain Res. 2012; 1453: 46-55. doi:10.1016/j.brainres.2012.03.009
- 58Wang L, Chen X, Zhang C, et al. Elevated expression of TRPC4 in cortical lesions of focal cortical dysplasia II and tuberous sclerosis complex. J Mol Neurosci. 2017; 62(2): 222-231. doi:10.1007/s12031-017-0923-z
- 59Sun F, Zhang C, Chen X, et al. Downregulation of CD47 and CD200 in patients with focal cortical dysplasia type IIb and tuberous sclerosis complex. J Neuroinflammation. 2016; 13(1): 85. doi:10.1186/s12974-016-0546-2
- 60Zhai F, Zhou J, Luan G. The preoperative assessment and surgical approaches of epilepsy induced by tuberous sclerosis complex. Zhong Hua Shen Jing Wai Ke Za Zhi. 2013; 29(6): 612-615 [in Chinese]. doi:10.3760/cma.j.issn.1001-2346.2013.06.027
10.3760/cma.j.issn.1001-2346.2013.06.027 Google Scholar
- 61 Neuromodulation Committee of China Association Against Epilepsy. Neuromodulation Committee of Chinese Medical Doctor Association, neurophysiology Group of Neurosurgery Branch of Chinese Medical Association. Chinese experts' consensus on vagus nerve stimulation in the treatment of drug-refractory epilepsy. Dian Xian Za Zhi. 2021; 7(3): 191-196 [in Chinese]. doi:10.7507/2096-0247.20210031
10.7507/2096-0247.20210031 Google Scholar
- 62Tong X, Wang X, Qin L, et al. Vagus nerve stimulation for drug-resistant epilepsy induced by tuberous sclerosis complex. Epilepsy Behav. 2022; 126:108431. doi:10.1016/j.yebeh.2021.108431
- 63Zheng H, Wang C, Bin J, et al. Deep brain stimulation of anterior thalamic nucleus for treatment of patient with tuberous sclerosis-related refractory epilepsy. World Neurosurg. 2020; 138: 141-144. doi:10.1016/j.wneu.2020.03.010
- 64Luo T, Wang X, Wang J, et al. Optimization and high-density array of stereoelectroencephalography-guided radiofrequency thermocoagulation for the treatment of pediatric tuberous sclerosis complex with epilepsy. CNS Neurosci Ther. 2022; 28(5): 724-731. doi:10.1111/cns.13804
- 65Zhang H, Li M, Du J, et al. Stereoelectroencephalography-guided three-dimensional radiofrequency thermocoagulation for the treatment of drug-resistant epilepsy. Zhong Hua Shen Jing Wai Ke Za Zhi. 2018; 34(12): 1197-1201 [in Chinese]. doi:10.3760/cma.j.issn.1001-2346.2018.12.003
10.3760/cma.j.issn.1001-2346.2018.12.003 Google Scholar
- 66Wang Y, Xu J, Liu T, et al. Magnetic resonance-guided laser interstitial thermal therapy versus stereoelectroencephalography-guided radiofrequency thermocoagulation for drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsy Res. 2020; 166:106397. doi:10.1016/j.eplepsyres.2020.106397
- 67Chen S, Wang Y, Fang X, et al. Safety and short-term efficacy of domestic magnetic resonance-guided laser interstitial thermotherapy in the treatment of drug-resistant epilepsy. Zhong Hua Yi Xue Za Zhi. 2021; 101(41): 3399-3403 [in Chinese]. doi:10.3760/cma.j.cn112137-20210501-01046
- 68Tovar-Spinoza Z, Ziechmann R, Zyck S. Single and staged laser interstitial thermal therapy ablation for cortical tubers causing refractory epilepsy in pediatric patients. Neurosurg Focus. 2018; 45(3): E9. doi:10.3171/2018.6.FOCUS18228
- 69Stellon MA, Cobourn K, Whitehead MT, Elling N, McClintock W, Oluigbo CO. “Laser and the tuber”: thermal dynamic and volumetric factors influencing seizure outcomes in pediatric subjects with tuberous sclerosis undergoing stereoencephalography-directed laser ablation of tubers. Childs Nerv Syst. 2019; 35(8): 1333-1340. doi:10.1007/s00381-019-04255-4
- 70Fayed I, Sacino MF, Gaillard WD, Keating RF, Oluigbo CO. MR-guided laser interstitial thermal therapy for medically refractory Lesional epilepsy in pediatric patients: experience and outcomes. Pediatr Neurosurg. 2018; 53(5): 322-329. doi:10.1159/000491823
